Company Quick10K Filing
Vilacto Bio
10-Q 2019-06-30 Filed 2019-08-19
10-K 2019-03-31 Filed 2019-07-10
10-Q 2018-12-31 Filed 2019-02-19
10-Q 2018-09-30 Filed 2018-11-19
10-Q 2018-06-30 Filed 2018-08-20
10-K 2018-03-31 Filed 2018-08-02
S-1 2018-03-30 Public Filing
10-Q 2017-12-31 Filed 2018-02-14
10-Q 2017-09-30 Filed 2017-11-08
10-Q 2017-06-30 Filed 2017-08-09
10-K 2017-03-31 Filed 2017-07-14
10-Q 2016-12-31 Filed 2017-02-17
10-Q 2016-09-30 Filed 2016-11-01
10-Q 2016-06-30 Filed 2016-08-04
10-K 2016-03-31 Filed 2016-07-08
10-Q 2015-12-31 Filed 2016-02-08
10-Q 2015-09-30 Filed 2015-11-06
10-Q 2015-06-30 Filed 2015-08-07
10-K 2015-03-31 Filed 2015-06-12
10-Q 2014-12-31 Filed 2015-02-05
10-Q 2014-09-30 Filed 2014-10-31
10-Q 2014-06-30 Filed 2014-07-18
10-K 2014-03-31 Filed 2014-06-02
10-Q 2013-12-31 Filed 2014-02-05
10-Q 2013-09-30 Filed 2013-10-30
10-Q 2013-06-30 Filed 2013-08-15
8-K 2019-01-07 Accountant, Exhibits
8-K 2018-12-28 Sale of Shares, Officers
8-K 2018-11-15 Officers, Exhibits
8-K 2018-11-09 Enter Agreement, M&A, Off-BS Arrangement, Sale of Shares, Exhibits
8-K 2018-02-26 Enter Agreement, Off-BS Arrangement, Sale of Shares, Exhibits
8-K 2017-04-10 Officers

Vilacto Bio Financials

VIBI Metrics, Comps, Filings

Quarterly | Annual

Business

We are a biotech company based in Denmark that has acquired a license to a patented molecule, known as the Lactoactive molecule, which has in numerous studies demonstrated above average effect in treating conditions such as inflammatory diseases, diabetics, psoriasis, and skin issues in different levels. We aim to further develop our Lactoactive molecule for the purpose of increasing the quality of our retail and medical skin cream products as well as developing products for medical applications.

We are currently marketing a line of our skin care products on our website at www.vilacto.com. These products include, lotions, skin care creams and gels, lip balms, foot creams and oils, and similar items. We have entered into an affiliate network program with Rakuten / LinkShare, whereby other websites in the industry will post links to our website.

We signed a license agreement with have Carmen Electra endorse our skin care products. On August 29, 2017, we signed an agreement with Rakuten Super Logistics (known as RSL) to handle our inventory, fulfillment and shipment. In June 2017, we upgraded our production facility to included additional storage containers, improved mixing machines and upscale filtration units. We have also attended skin care products to market our products to the industry.


Valuation ($MM)

Market Cap, Enterprise Value

Balance Sheet ($MM)

Assets, Equity

Income Statement ($MM Quarterly)

Revenue, G Profit, Net Income

Cash Flow ($MM Quarterly)

Ops, Inv, Fin

Comps ($'000 TTM) Market Cap Gross Margin EV/EBITDA Ret on Assets Assets Liabilities Revenue G Profit Net Income EBITDA EV
Mercantil Bank Holding (MBHC) 0 -1.3 0% 8,435,802 7,708,127 0 0 21,974 81,045 -103,579
Bill.com (BILL)
ProGreen (PGUS) 0 0% -0.1 -176% 1,863 6,266 61 0 -3,277 -210 17
9F (JFU)
OriginClear (OCLN) 0 11% -0.4 -648% 1,287 20,610 2,696 290 -8,338 -7,771 3,125
Blue Hat Interactive (BHAT)
Daniels Corporate Advisory (DCAC) 0 22% -0.4 50% 547 2,757 2,368 525 271 343 -129
Yinghong Guangda Technology (UBLI) 0 24% 0.0 0 21 1,377 326 -1,329 -1,280 -0
Ironclad Encryption (IRNC) 0 0.0 -1,440% 585 5,116 0 0 -8,421 -7,101 -150
HyperSolar (HYSR) 0 1.4 131% 174 6,528 0 0 228 1,247 1,711
Alkame Holdings (ALKM) 0 11% -0.0 -2,776% 97 4,532 124 13 -2,695 -2,645 0
Vilacto Bio (VIBI) 0 17% -0.0 -3,636% 538 3,960 5 1 -19,550 -19,519 17
Futu (FHL)
Afya (AFYA)
PetLife Pharmaceuticals (PTLF) 0 -0.1 -47,202% 8 1,981 0 0 -3,708 -3,708 205
Rennova Health (RNVA) 0 8% -1.3 -236% 16,574 76,464 13,138 1,065 -39,132 -22,172 28,583
Cerebain Biotech (CBBT) 0 -2.4 -7,969% 22 6,686 0 0 -1,718 -1,399 3,294
Kibush Capital (DLCR) 0 33% -0.2 -213% 178 3,452 140 46 -380 -374 88
Coates (COTE) 0 0% 0.0 -247% 2,206 8,851 10 0 -5,451 -4,482 -18
FinServ Acquisition (FSRVU)

Balance Sheet ($'000)2013-06-302013-09-302013-12-312014-03-312014-06-302014-09-302014-12-312015-03-312015-06-302015-09-302015-12-312016-03-312016-06-302016-09-302016-12-312017-03-312017-06-302017-09-302017-12-312018-03-312018-06-302018-09-302018-12-312019-03-31
Cash8273814910030000002232714949143128257
Accounts Receivable000000
Inventory
PP&E
Assets8273914101003000101223136207310198284412538
Accounts Payable01343333373395112436315416876
Long-Term Debt33120302550275
Liabilities0000136917172025293336651193104831,2461,0823,4924,6153,960
Stockholders' Equity82739139-2-5-9-14-17-20-25-29-33-35-43-116-175-276-936-883-3,208-4,203-3,423
Income Statement ($'000)2013-06-302013-09-302013-12-312014-03-312014-06-302014-09-302014-12-312015-03-312015-06-302015-09-302015-12-312016-03-312016-06-302016-09-302016-12-312017-03-312017-06-302017-09-302017-12-312018-03-312018-06-302018-09-302018-12-312019-03-31
Revenue000000000000000010112
Cost of Revenue00000112
Gross Profit0001001-0
R&D
SG&A116211121112021119154728675110083
Tax00000000000000000000000
Net Income-7-3-16-25-51-3-4-5-3-3-5-4-4-3-11-73-59-101-66053-2,325-3,072-14,206
Cash Flow ($'000)2013-06-302013-09-302013-12-312014-03-312014-06-302014-09-302014-12-312015-03-312015-06-302015-09-302015-12-312016-03-312016-06-302016-09-302016-12-312017-03-312017-06-302017-09-302017-12-312018-03-312018-06-302018-09-302018-12-312019-03-31
Cash Operating-6-3-16-25-4-9-2-4-5-3-3-4-1-8-3-2-77-23-121-117-102-194-118
Cash Investing00-10-5-8-15
Cash Financing1572801502480350832358221272597297262